Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma

Table 2 Clinical characteristics of primary gastrointestinal diffuse large B-cell lymphoma patients

Clinical characteristics	n	DP	Non-DP	χ2	P
Patients	60	18	42
Age (yr)				2.534	0.111
≤ 60	34	13	21
> 60	26	5	21
Gender				0.051	0.821
Male	32	10	22
Female	28	8	20
Primary site				0.013	0.908
Stomach	36	11	25
Intestinal	24	7	17
Lugano staging system				22.781	< 0.0001
I-II2	36	2	34
IIE-IV	24	16	8
LDH				0.207	0.649
Normal	34	11	23
Elevated	26	7	19
B symptoms				0.277	0.599
Positive	7	1	6
Negative	53	17	36
IPI				2.286	0.131
0-2	50	13	37
3-5	10	5	5
Pathological type				2.188	0.139
Non-GCB	48	17	31
GCB	12	1	11
CD10 status				0.013	0.908
Positive	36	117	25
Negative/NA	24		17
CD5 status				2.265	0.127
Positive	49	13	36
Negative/NA	11	5	6
CD20 status				0.207	0.649
Positive	34	11	23
Negative/NA	26	7	19
Anemia				0.003	0.955
Present	33	10	23
Absent	27	8	19
Treatment				2.017	0.156
ST + CT	51	13	38
ST + CT + RT	9	5	4
Therapeutic evaluation
CR	48	9	39	11.910	0.001
PR/SD/PD	12	9	3

DP: MYC/BCL-2 protein double positive; Non-DP: Non-MYC/BCL-2 protein double positive; NA: Not available; ST: Surgery; CT: Chemotherapy; RT: Radiotherapy; CR: Complete remission; PR: Partial remission; SD: Stable disease; PD: Progressive disease.